GPT and metabolic dysfunction-associated steatohepatitis: Tirzepatide, a synthetic GLP1/GIP peptide agonist, effectively reduced ALT and AST, increased adiponectin levels, resulting in significant improvement of liver fat content in T2DM sufferers with NASH [77].